31450171Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler TOral oncologyAfatinib; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and NeckAged; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Methotrexate; Quinazolines; Treatment Adherence and Compliance; Treatment OutcomeAfatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91.Oral Oncol2019-08-23T00:00:002019Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000368Living Beings1341183530.294764AgedD000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsD008727Chemicals & Drugs772490.929412MethotrexateAuthorship 13256770.1817860.1817861authors10.2513has subject areaD005260Physiology1992444050.191167FemaleD006258Disorders15210510.576772Head and Neck NeoplasmsD006801Living Beings2262862810.130052HumansD008297Physiology1931408600.201617MaleD016896Concepts & Ideas101179490.402389Treatment OutcomeD009364Disorders33613050.61985Neoplasm Recurrence, LocalD011799Chemicals & Drugs652200.877229QuinazolinesD000074822550.994199Treatment Adherence and ComplianceD066246Chemicals & Drugs1494850.779528ErbB ReceptorsD018572Concepts & Ideas25812030.792696Disease-Free SurvivalMedicineUniversity of ChicagoEzraCohenEzra Cohen41.78927490000000-87.601250000000001350Cohen, EzraASSOCIATE PROFESSORtrue1ASSOCIATE PROFESSORASSOCIATE PROFESSOR